Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost people notice Wegovy starting to work within the first one to four weeks, though the clearest appetite changes tend to build over the first two to three months as the dose increases. Semaglutide works gradually by design: it mimics a gut hormone that signals fullness, and its full effect arrives alongside dose escalation, not on day one. These are prescription-only medicines; a prescriber assesses whether they're right for you before treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Picture this: you've taken your first Wegovy injection, you've put the pen back in the fridge next to last night's leftovers, and you're waiting to feel something dramatic. For most people, that drama doesn't arrive straight away, and that's entirely intentional.
Wegovy's active ingredient, semaglutide, is a GLP-1 receptor agonist. It attaches to the same receptors that your gut's own GLP-1 hormone uses after a meal to signal the brain that you're full and slow the rate at which your stomach empties. At the starting dose of 0.25mg, the medicine is getting your system accustomed to it, not yet asking it to work hard. Some people do notice a slight reduction in appetite in the first week. Others feel very little. Both are normal.
What is happening biochemically, even if you can't feel it, is that semaglutide is binding to receptors in the hypothalamus and gut and beginning to shift the hormonal signals that govern hunger. The process is cumulative. Think of it less like a switch and more like turning a dial, slowly, across weeks. The full Wegovy overview covers how the medicine is licensed and what the dose pathway looks like in practice.
By the time a second or third injection arrives, many people start describing a qualitative shift: meals feel satisfying sooner, the background hum of hunger that used to occupy the afternoon quietens down, snacking feels less compulsive. These are the early signs that semaglutide is beginning to work at a level you can actually feel.
The dose escalation schedule (typically moving from 0.25mg up through 0.5mg, 1.0mg, 1.7mg and eventually 2.4mg, with roughly four weeks at each level) is designed to let your body adjust and to reduce gastrointestinal side effects. Weight loss tends to become measurable around week four to eight for most people, though this varies. Some see the scale move sooner; others find weeks three and four produce the first visible change.
The question of how soon Wegovy kicks in doesn't have a single answer, because "kicking in" means different things: the appetite signal arriving, the scale moving, or reaching a weight that reflects a clinically meaningful reduction. These happen at different times. Side effects (nausea in particular) can also arrive in these early weeks as the gut adjusts, and are a signal, in their own way, that the medicine is active.
For practical guidance on timing injections and building a consistent weekly routine, the Wegovy timing and dosing routine page is worth reading alongside this one.
The STEP 1 trial, published in the New England Journal of Medicine, ran for 68 weeks and found an average body-weight reduction of around 15% at the 2.4mg maintenance dose. That headline figure is a 68-week result, it doesn't mean 15% arrives by month one.
Clinicians typically assess whether semaglutide is working at around the six-month mark on the maintenance dose. NICE guidance on semaglutide suggests reviewing whether to continue if weight loss is less than 5% after six months at the highest tolerated dose, as described on the NICE semaglutide appraisal (TA875). This is a useful benchmark for anyone asking "when does semaglutide kick in" in the longer sense of producing a clinically meaningful response.
For a broader look at the factors that shape how well weight-loss treatment works over time (including diet, activity, and what to expect at different stages) our weight-loss overview goes into more detail. One thing worth keeping in mind: muscle mass matters during treatment, and questions about body composition during this period are worth raising with a prescriber. Our page on Wegovy and muscle wasting addresses what the evidence actually shows.
A common reason people feel Wegovy hasn't kicked in yet is that they're still on a low escalation dose. At 0.25mg or 0.5mg, the appetite effect is deliberately modest. The medicine isn't failing, it's building. If you're several weeks into treatment and genuinely concerned that nothing is changing, the right conversation is with your prescriber, not a higher self-administered dose.
It's also worth separating different types of "not working": not feeling less hungry is different from not losing weight despite eating less, which is different again from losing weight but more slowly than you expected. Each has a different clinical explanation. The detailed semaglutide timeline page breaks this down further if you want a day-by-day picture of what's typical in early treatment.
If you haven't started treatment yet and are weighing up whether Wegovy is right for you, a prescriber can give you a realistic picture of what to expect for your specific situation. Speak to our prescribers through a free consultation at our treatment page, your answers are read by a real clinician the same day, not processed by software.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.